If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenincode Regulatory News (GENI)

Share Price Information for Genincode (GENI)

Share Price is delayed by 15 minutes
Get Live Data
0.95    -0.02 (-2.11%)
Bid:
0.90
Ask:
1.00
Spread: 0.10 (11.111%)
Market Cap: £7.00m
GENI Live PriceLast checked at - London Stock Exchange

Intraday Genincode Share Chart

Holding(s) in Company

15 Jan 2024 07:00

RNS Number : 6138Z
GENinCode PLC
15 January 2024
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

GENinCode Plc

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Foresight Group LLP

City and country of registered office (if applicable)

London, UK

4. Full name of shareholder(s) (if different from 3.) v

Name

Thames Ventures VCT 1 plc,

Thames Ventures VCT 2 plc (Healthcare)

City and country of registered office (if applicable)

London, UK

5. Date on which the threshold was crossed or reached vi:

10.01.24

6. Date on which issuer notified (DD/MM/YYYY):

11.01.24

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

5.78%

5.78%

10,236,864

Position of previous notification (if

applicable)

10.68%

10.68%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Ordinary GB00BL97B504

10,236,864

n/a

5.78

n/a

SUBTOTAL 8. A

10,236,864

5.78

 

 

 

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

n/a

n/a

n/a

n/a

n/a

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

n/a

n/a

n/a

n/a

n/a

n/a

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

 

 

 

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Foresight Group Holdings Limited

Foresight Holdco 2 Limited

Foresight Group LLP

5.78

0.00

5.78

 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional information xvi

N/A

 

Place of completion

London, UK

Date of completion

11.01.24

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFFFLILSISLIS
Date   Source Headline
1st Jul 20261:30 pmRNSResult of AGM
11th Jun 20265:42 pmRNSHolding(s) in Company
10th Jun 20264:53 pmRNSHolding(s) in Company
8th Jun 20267:00 amRNSFinal Results
4th Jun 20266:02 pmRNSHolding(s) in Company
3rd Jun 202611:03 amRNSHolding(s) in Company
22nd May 20267:00 amRNSNotice of Results
8th May 20264:06 pmRNSHolding(s) in Company
7th May 20267:00 amRNSGrant of Share Options & PDMR Dealings
15th Apr 202612:16 pmRNSHolding(s) in Company
14th Apr 20262:09 pmRNSHolding(s) in Company
26th Feb 20263:30 pmRNSHolding(s) in Company
24th Feb 20262:28 pmRNSHolding(s) in Company
12th Feb 20264:07 pmRNSHolding(s) in Company
12th Feb 20263:46 pmRNSHolding(s) in Company
12th Feb 20263:45 pmRNSHolding(s) in Company
9th Feb 202612:13 pmRNSResult of GM, Director Shareholdings and TVR
6th Feb 20262:39 pmRNSAdditional Subscription
26th Jan 20263:00 pmRNSResult of Retail Offer
22nd Jan 20268:24 amRNSResult of Placing and Subscription
21st Jan 20265:26 pmRNSRetail Offer
21st Jan 20265:23 pmRNSPlacing and Subscription
17th Dec 20257:28 amRNSCollaboration with Sohin Genetics
8th Dec 20251:42 pmRNSHolding(s) in Company
4th Dec 20257:00 amRNSCollaboration with Thermo Fisher
3rd Dec 20257:00 amRNSApproval of CARDIO inCode-score in New York state
27th Oct 20257:00 amRNSPublication of Landmark Study in JACC: Advances
13th Oct 20254:21 pmRNSHolding(s) in Company
30th Sep 20257:00 amRNSHalf-year Report
25th Sep 20257:00 amRNSNHS (UCLH) Risk of Ovarian Cancer (ROCA) launch
24th Sep 20255:58 pmRNSHolding(s) in Company
17th Sep 202510:42 amRNSStmnt re Share Price Movement
5th Sep 20257:00 amRNSNotice of Results
26th Aug 20257:00 amRNSTrading update
7th Jul 20257:00 amRNSDe Novo Update – FDA Supervisory Review
30th Jun 202511:42 amRNSResult of AGM
4th Jun 20257:00 amRNSFinal Results
16th May 20257:00 amRNSNotice of Results
30th Apr 20257:00 amRNSDe Novo Submission Update
26th Mar 20257:45 amRNSGrant of Share Options & PDMR Dealings
6th Mar 20252:24 pmRNSHolding(s) in Company
5th Mar 20253:02 pmRNSHolding(s) in Company
4th Mar 20251:16 pmRNSHolding(s) in Company
3rd Mar 202512:54 pmRNSResult of General Meeting, Issue of Equity and TVR
18th Feb 20257:00 amRNSResult of Retail Offer
14th Feb 202510:01 amRNSResult of Placing and Subscription
14th Feb 20257:05 amRNSRetail Offer
14th Feb 20257:00 amRNSPlacing and Subscription
23rd Jan 20257:00 amRNSCARDIO inCode Lab Fee Update & Catalonia Launch
10th Dec 20247:00 amRNSPartnership with Genesupport SA for the ROCA® Test

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.